Join to View Full Profile
6445 Main StFloor 24Houston, TX 77030
Phone+1 713-441-9948
Fax+1 713-441-8791
Dr. Geyer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Baylor College of MedicineFellowship, Hematology and Medical Oncology, 1984 - 1986- Baylor College of MedicineFellowship, Hematology, 1984 - 1984
- Baylor College of MedicineResidency, Internal Medicine, 1980 - 1983
Texas Tech University Health Sciences Center School of MedicineClass of 1980
Certifications & Licensure
PA State Medical License 2002 - 2026
TX State Medical License 1980 - 2024
VA State Medical License 2013 - 2024
FL State Medical License 2013 - 2015
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
National Board of Physicians and Surgeons Internal Medicine- National Board of Physicians and Surgeons Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer Start of enrollment: 2014 Apr 22
- Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer Start of enrollment: 2019 Apr 05
Publications & Presentations
PubMed
- Assessment of Adjuvant Endocrine Therapy With Ovarian Function Suppression by Breast Cancer Index.Ruth M O'Regan, Yue Ren, Yi Zhang, Natalia Siuliukina, Catherine A Schnabel
JAMA Network Open. 2025-11-03 - 1 citationsPredicting ovarian function loss after chemotherapy and anti-HER2 therapy in young breast cancer patients.Matteo Lambertini, Deirdre Allegranza, Ruediger P Laubender, Nadia Harbeck, Sandra M Swain
Journal of the National Cancer Institute. 2025-08-12 - 8 citationsClinical and Genomic Risk for Late Breast Cancer Recurrence and Survival.Joseph A Sparano, Michael Crager, Robert J Gray, Gong Tang, Jess Hoag
NEJM Evidence. 2024-08-01
Journal Articles
- Association of Immunophenotype with Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast CancerCharles E Geyer, William M Sikov, JAMA Oncology
Lectures
- NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in patients (pts) with ...2019 ASCO Annual Meeting - 6/1/2019
- NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in Patients (pts) with ...2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
HER2-Positive Early Breast Cancer: Trastuzumab Deruxtecan Moves Into Earlier Clinical SettingsOctober 27th, 2025- Trastuzumab Deruxtecan Scores Two Wins in HER2-Positive Early Breast CancerOctober 19th, 2025
- ENHERTU® Reduced the Risk of Disease Recurrence or Death by 53% Versus T-dM1 in Patients with High-Risk HER2 Positive Early Breast Cancer Following Neoadjuvant Therapy in DESTINY-Breast05 Phase 3 TrialOctober 18th, 2025
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
